No products in the cart.
30
Nov
Nov
Nov. 29, 2021 — Merck’s antiviral tablet for COVID-19, molnupiravir, seems to be far much less efficient than early outcomes from the scientific trial first urged. According to an evaluation by scientists on the FDA, the experimental tablet lower the chance of hospitalization or dying from COVID-19 by about 30%, in comparison with a placebo, […]